Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | SCN4A | P35499 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289867 | 0.86 | SOS1 (0.58) | HSPB1SOS1SCN4AFFAR1FFAR4 | |
| SCHEMBL6290683 | 0.86 | SOS1 (0.58) | HSPB1SOS1SCN4AFFAR1FFAR4 | |
| SCHEMBL351854 | 0.86 | SOS1 (0.58) | HSPB1SOS1SCN4AFFAR1FFAR4 | |
| SCHEMBL7367702 | 0.83 | SOS1 (0.56) | HSPB1SOS1SCN4AFFAR1FFAR4 | |
| SCHEMBL239776 | 0.83 | — | — | |
| SCHEMBL6842201 | 0.78 | MAPT (0.45) | HSPB1SOS1FFAR1FFAR4MEN1 | |
| SCHEMBL31655464 | 0.78 | SOS1 (0.52) | HSPB1SOS1SCN4AMEN1KMT2A | |
| SCHEMBL10355134 | 0.77 | SOS1 (0.59) | HSPB1SOS1FFAR1FFAR4MEN1 | |
| SCHEMBL255272 | 0.76 | LTA4H (0.67) | HSPB1SOS1FFAR1FFAR4L3MBTL1 | |
| SCHEMBL347785 | 0.76 | LTA4H (0.67) | SOS1FFAR1HTTLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| CN-106554382-B | Application in nucleoside phosphoramidite class compound and preparation method thereof and drug | 四川科伦博泰生物医药股份有限公司 | 2019-12-03 | — | — | CN | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | THE CLEVELAND CLINIC FOUNDATION | 2016-11-03 | — | — | US | claimed |
| WO-2015095757-A1 | TREATMENT OF RETINOPATHY OF PREMATURITY (ROP) | THE CLEVELAND CLINIC FOUNDATION (US) | 2015-06-25 | — | — | WO | claimed |
| CN-102977015-B | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin | FIBROGEN INC | 2015-05-06 | — | — | CN | claimed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-07-11 | — | — | US | claimed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| CN-1816527-A | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin | FIBROGEN INC (US) | 2006-08-09 | — | — | CN | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | HSPB1 1234/4885SOS1 1789/4885SCN4A 3638/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | HSPB1 1234/4885SOS1 1789/4885SCN4A 3638/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | HSPB1 1234/4885SOS1 1789/4885SCN4A 3638/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | HSPB1 1040/4885SOS1 1619/4885SCN4A 3479/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | HSPB1 1234/4885SOS1 1789/4885SCN4A 3638/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | HSPB1 1040/4885SOS1 1619/4885SCN4A 3479/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | HSPB1 1234/4885SOS1 1789/4885SCN4A 3638/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | HSPB1 2101/4885SOS1 3114/4885SCN4A 2458/4885 |
| US-20160317523-A1 | Treatment of Retinopathy of Prematurity (ROP) | VEGFA, ALDH1A2, PGF | HSPB1 1036/4885SOS1 1298/4885SCN4A 4131/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | HSPB1 607/4885SOS1 3081/4885SCN4A 3234/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | HSPB1 1218/4885SOS1 2455/4885SCN4A 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.